International Journal of Pharmaceutical Sciences and Nanotechnology

[Revised June 26, 2011]

Instructions to Authors

PLEASE NOTE NEW MANUSCRIPT SUBMISSION PROCEDURES AND INSTRUCTIONS: Communication with Chief Editor
field, integrating basic background principles and practice, or summarizing with a critical analysis of the field or consensus view of controversial topics in pharmaceutical field. Review articles should provide comprehensive and updated information of the topic that and be presented in a quite useful format for researchers, students, industrial scientists, and others professionals. Broad topic areas including new drug monographs, nanotechnology or novel drug delivery systems are particularly encouraged. There is no specific structure or format for Review Articles, but it should carry major headings, subheadings and headings of topic discussions with suitable reference citations. Manuscripts must not be more than 30 double-spaced pages including references (excluding figures and tables).

Manuscript correspondence should be submitted to: Dr. Samba Reddy Chief Editor, International Journal of Pharmaceutical Sciences and

Texas A&M Health Science Center, College of Medicine, College Station, Texas, USA E-mail: reddysamba@gmail.com

Nanotechnology

Scope and Coverage of Manuscripts

The IJPSN invites manuscripts dealing with broad areas and all aspects of pharmaceutical sciences, furthering research into the nanotechnology systems. All aspects of pharmaceutics, biopharmaceutics, industrial pharmacy, clinical pharmacy, pharmacology and therapeutics, toxicology, pharmaceutical chemistry, phytochemical investigations, medicinal and analytical chemistry, pharmacy administration and pharmacoeconomics, pharma biotechnology, recombinant drugs, and all aspects of nanotechnology-based drug formulation design and delivery systems are considered for publication in the Journal. Manuscripts that were previously published in part or full or papers that are under consideration elsewhere are NOT acceptable. The Journal considers the following two broad categories of manuscripts for publication: (i) Research Papers: These are manuscripts predominantly devoted to reporting ORIGINAL research investigations in the pharmaceutical and biomedical sciences, including research in one of the core pharmaceutical sciences (pharmaceutics, biopharmaceutics, industrial pharmacy, clinical pharmacy, pharmacology and therapeutics, toxicology, pharmaceutical chemistry, phytochemical investigations, medicinal and analytical chemistry, pharmacy administration and pharmacoeconomics, pharma biotechnology, novel drug delivery, drug discovery; clinical trials of therapeutic agents, diagnostic techniques, behavioral, epidemiological or educational aspects of pharmacy). Papers from clinical or pharmacy practice or any related pharmaceutical topics will be considered for publication. Basic science research with pharmaceutical applications is also considered for publication. The manuscript should adhere to the following format and page limitations (see below). Review Articles: Review articles should contain the current state of knowledge or recent advances in the

Submission of Manuscripts
All manuscript submissions must be made through the journal's online manuscript submission system at: http://www.ijpsnonline.com/manu_sub.php If you are not familiar with the online system, send manuscripts by e-mail to the Chief Editor: reddysamba@gmail.com If you are using the online system for the first time, you must create an account before you can submit a paper. To do so, please click on LOGIN page, then "Register with us". Complete creating your account information including a user name and password. Then, submit your manuscript online as per the instructions provided. Upload your manuscript file and figures. High-resolution figures should be submitted with each manuscript. After submitting your manuscript online, you will receive an automatic e-mail acknowledgement. Further enquiries should be sent to the Chief Editor (reddysamba@gmail.com). A scanned copy of the Copyright Form signed by the correspondent author and ALL co-authors should be submitted along with the manuscript. A PDF copy of the Copyright Form is available online (see Instructions for Authors). Submission of a manuscript represent an assurance that the paper has received the author's institutional permissions, if any, has not been copyrighted, published, or accepted for publication elsewhere, is not currently being considered for publication in other journals, and will not be submitted to any other journal while under review and consideration by the International Journal of Pharmaceutical Sciences and Nanotechnology.

(ii)

Organization of the Manuscript

Manuscripts must be in English, typewritten using Arial or Times New Roman fonts only, and double-spaced throughout, including references, tables, and figure legends. Manuscripts should contain the following sections in the order listed. Each section should begin on a new page and all pages should be numbered consecutively. 1. Title page. This page should contain the complete title of the article, the names of all authors, and their institutional address and the address of the correspondence author. The title page should contain the following: a) Article title it should be brief and convey the overall finding or nature of the manuscript or research study. Indicate on the top Research Paper or Review Article as appropriate. b) Names of all authors and their institutional address. Departmental or institutional affiliation should be indicated by author initials only. c) A running title, which conveys the sense of the full title (not to exceed 10 words) may be used. d) The name, address, telephone and e-mail address of the corresponding author. e) The number of text pages, number of tables, figures, and references, and the number of words in the Abstract, Introduction, and Discussion (provide each item on a separate line). 2. Abstract. The abstract should concisely present the background of the topic, purpose of the study, research rationale, general methods, results, and conclusions. The abstract should not exceed 300 words. The abstract must be a single paragraph. Key words: Provide 6 to 10 key words of the research paper. Abbreviations: Provide a list of abbreviations used in the manuscript. (The use of abbreviations should be minimized) 3. Introduction. The Introduction section must contain a brief description of the relevant background that supports the rationale of the study. It must contain a clear description of the aims and objectives of the research paper or review article. The length of the Introduction section (2 to 3 paragraphs) should not exceed 1000 words. 4. Materials and Methods. The Methods or Experimental section should contain complete descriptions of all methods and procedures used in the study. They should accompanied with suitable references of the established or new methodology used, including the citation of th e original source. The methods section should be organized under major headings (In vitro studies; In vivo studies; Pharmacology testing, etc). Note: Descriptions of methods must be sufficient to judge the accuracy, reproducibility, and reliability of the experiments. The name and address (city and state or country) of commercial suppliers of chemicals, drugs, reagents, or drug samples and all equipment used must be listed in the Methods section. There is no word limitation for Methods section. 5. Results. The Results section should describe the experimental data and their statistical significance as appropriate. Use paragraphs with headings stating the main findings. Results should be illustrated in figures or tables but duplication should be

avoided. The description of experimental findings should use standard abbreviations as listed on the Abstract page. Use units consistently throughout the manuscript. Generally, units are abbreviated without punctuation and with no distinction between singular and plural forms (e.g., 5 ml; 5 mg; 5 mg/ml; 5 mg/kg etc). Sufficient data should be presented to allow for judgment of the variability and reliability of the results. Statistical probability (p) in tables, figures, and figure legends should be expressed as *p < 0.05, **p < 0.01, and ***p < 0.001. For second comparisons, one, two, or three daggers may be used. For multiple comparisons within a table, footnotes italicized in lower case, superscript letters are used and defined in the table legend. There is no word limitation for the Results section, but a succinct description would look better for reading. 6. Discussion. The Discussion section should describe the main conclusions drawn from the findings and their relevance to the field or advancing the field. The main findings must be integrated with the current literature with a positive and negative confirmation or new findings with suitable literature references to support the new contentions or findings. It should be brief and the description should be based on the data presented. The Discussion section (3-6 paragraphs) should not exceed 2000 words. 7. Acknowledgments. The Acknowledgments section should be placed at the end of the text. Personal, technical or reagent help and assistance is noted here. Grants or financial support is acknowledged in this section. For example: This work was supported by the UGC Fellowship or CSIR Fellowship or AICTE grant to ABC (author initials). 8. References. References should be cited in the text by giving the first author's name (or the first and second if they are the only authors) and the year of publication (e.g., Reddy and Kulkarni, 1998; Carver, 2006; or Kennedy et al., 2010). In the reference list, the references should be arranged alphabetically by author (they should not be numbered). The names of all authors should be given in the reference list. If reference is made to more than one publication by the same author(s) in the same year, suffixes (a, b, c, etc.) should be added to the year in the text citation and in the references list (e.g., Rao et al., 2010a; 2010b). Journal titles should be abbreviated as given in the PubMed abstract citations (see www.PubMed.Gov). The total number of references should be less than 100 references (this rule not applicable to Review articles, which may contain up to 300 references). The authors are responsible for the accuracy of the references. The format for journal article, book chapter, and books is as follows:

Journal article:

Fricks IP, Maddileti S, Carter SRL, Lazarowski ER, Nicholas RA, Jacobson KA, and Harden TK (2008). UDP is a competitive antagonist at the human P2Y14 receptor. J Pharmacol Exp Ther 325: 588- 594.

Book Chapter:

Kappas A (2002). Development of heme oxygenase inhibitors for the prevention of sever jaundice in infants: studies from laboratory bench to newborn nursery. In Heme Oxygenase in Biology and Medicine (Abraham NG, Alam J, and Nath KA eds), Kluwer Academic/Plenum Publishers, New York, pp 3-17.

Book:

Wilson JH and Hunt T (2008). Molecular Biology of the Cell: A Problems Approach, 5th ed. Garland Science, New York.

Note: Websites or URL addresses as reference citations are NOT acceptable.

9. Tables. Each table should be double-spaced and formatted as Table on a separate page. Tables should be placed at the end of the manuscript after the References section. Tables are numbered consecutively with Arabic numerals. A brief descriptive title should be provided at the top of each table. General statements about the table follow the title in paragraph form. Footnotes to tables are referenced by italicized, lower case, superscript letters and defined beneath the table. 10. Legends for Figures. Each figure should be numbered consecutively with Arabic numerals and listed in order on the same page in continuation. Legends must provide a clear explanation of each figure with brief title and other related information, including appropriate statistical markings (e.g., *p<0.01 vs control). The type of statistical tests used may be indicated in the legend. 11. Figures. All figures should be prepared using professional software (Excel, SigmaPlot, GraphPad, Origin etc). Each figure must be uploaded as a separate file in a 1000 DPI resolution in the standard TIFF or JPG format. Figures should be ready for direct reproduction without further changes (editorial changes will not be made to figures). Each figure should be scaled to fit an 8.5 x 11 inch page (it should fit either in a 3.5 inch SIGNLE column or 7 inch DOUBLE columns of a printed page). Label figure files with the figure number and author name. Lettering on figures should be large enough to be legible after reduction to single or double column formatting. Photos, photomicrographs, and electron micrographs must be labeled with a magnification calibration (scale bar) in micrometers, nanometers or Angstrom units. A statement concerning the magnification (e.g., 10 m; 10 nm; 10 A) must appear in the figure legend. NOTE: Color figures will be published in the online version only. The print version is set for gray scale (B&W format) printing. NOTE: EXCEPT FOR COLOR PHOTOS AND PHOTOMICROGRAPHS, ALL DATA FIGURES, DIAGRAMS AND ILLUSTATIONS SHOULD BE PREPRAED IN GRAY SCALE OR BLACK & WHITE ONLY.

suggested expert reviewers who are familiar with the research study and are willing to review the manuscript, if invited by the Chief Editor. They may or may not be invited to review the manuscript, but it is very helpful to expedite the peer-review process. The final selection of reviewers will be done by the Chief editor or Review editors handling the manuscript. The list should contain the following details: Name, position, institutional address and e-mail ID.
NOTE: The corresponding author may indicate suggested reviewers and may also indicate reviewers who should be excluded. Reviewers should be suggested from outside of the institution including USA and other countries. Collaborators and persons with significant conflict-of-interest should not be listed as reviewers. The final choice of reviewers is at the discretion of the chief or review editor.

Other Instructions
Generic names of drug should be used in manuscript. Brand names may be given in parentheses following the first text reference, but should not appear in titles, figures, or tables. Trade names are capitalized, but generic or chemical names are not. The chemical structure of new compounds must be given. The form used in calculating concentrations (e.g., base or salt) must be indicated. Manuscripts Processing. Each manuscript will be reviewed by two independent experts in the field of pharmaceutical sciences. The reviewers are asked to evaluate the scientific merit of the study and provide suggestions for revision or improvements in the manuscript. The Chief Editor, upon consultation with Review Editors, will take the final decision about the acceptance and suitability of the manuscript for publication. If the Chief Editor requests for revisions, the authors must submit revised manuscripts within the designated time, generally within 90 days, and must contain an itemized list of all changes made as per the reviewers' suggestions. Acceptance and Page Proofs. The Chief Editor will send an email message about the acceptance or rejection of the manuscript or need for a revised version. All accepted manuscripts will be forwarded to the Publisher for setting up the page proofs as per the Journal style. Page proofs will be sent to the Correspondent Author by e-mail. Page proofs should be printed out, corrected, and returned to the Publisher (a scanned copy may be sent by e-mail to the Publisher). Page proofs must be returned within 5 days after receipt. The author will receive a PDF file of their paper published in the Journal. Print copies of the reprints may be ordered from the Publisher.

List of Expert Reviewers

Each manuscript should be accompanied by a list of expert reviewers or researchers in the field. Provide at least four (4) Submission Checklist ____ Letter of submission (cover letter to the Chief Editor)

----List of Suggested Expert Reviewers (name, position, address and e-mail of four research experts) ____ Manuscript file (Title page, Abstract, Introduction, Results, Discussion, References and Tables) ____ Manuscript Figures (each as a separate file, tiff or jpg format, minimum resolution 1000 dpi, Gray scale or B&W only) ____ Manuscript proof reading (read the manuscript for spelling mistakes) ____ Reference citations (check the manuscript for proper reference citations, see Author Instructions) ____ Reference checking (all references checked for accuracy and style, see Author Instructions, above) ____ Copyright Form (send a scanned copy of Copyright Form signed by ALL authors)

Pharma Book Syndicate

An unit of BSP Books Pvt., Ltd.

International Journal of Pharmaceutical Sciences and Nanotechnology Copyright Form

Manuscript Title ___________________________________________________________________________________________ __________________________________________________________________________________________________________ Name of Corresponding Author: _____________________________________________________________________________ Institution Name and Address: _______________________________________________________________________________ E-mail: __________________________________ Phone Number: __________________________________________________ Publishers Note
The Corresponding Author, on behalf of all co-authors, must read and sign below indicating his/her approval of copyright assignment. It is the responsibility of the Corresponding Author to share this document and distribute to co-authors for information and consent. Please include the Copyright Form with the manuscript at the time of submission. This Copyright agreement shall be effective when signed below, provided the final manuscript is accepted for publication in the Journal.

Copyright Assignment
In consideration of Pharma Book Syndicate (The Publisher) reviewing, editing, and publishing this manuscript (The Manuscript) in the International Journal of Pharmaceutical Sciences and Nanotechnology, when and if the Work is accepted for publication, the undersigned Corresponding Author (The Author) agrees to the following terms, as established by the journal Publisher. (1). The Author warrants that his/her contribution is original; that he/she has full power to make this Manuscript; that the Manuscript contains no defamatory or otherwise unlawful matter. (2) The Author hereby certifies that the Manuscript has not been previously published in any print or electronic journal or elsewhere, and is not copied from any previously published paper. (3). The Author hereby grants and assigns to the Publisher or its successors, Global Perpetual rights for print and other media to the Manuscript, including those protected by the copyright laws of India or any foreign country. (4). The Author has the right to use part of his/her Manuscript for any scholarly or academic purpose, such as use for instructional purposes or incorporation as part of another and different publication, provided this Manuscript reference is properly cited as required. (5) The Publisher may grant third parties permission to copy all or part of the Manuscript. If such permission is given, the Publisher will inform the Author of such permission. (6) The Author will NOT receive any royalty or other monetary compensation from the Publisher for the publication of the Manuscript and for the copyrights transferred by this Agreement. (7) In the case of an Institutional permission is needed for publication of the Manuscript, the Author is responsible for getting all necessary clearances from his/her institution and furnish the approval certificates if desired for verification or auditing purpose. (8) In the case of a Manuscript supported by funding from the U.S. National Institutes of Health (NIH), Wellcome Trust, the Howard Hughes Medical Institute, or the UK Research Councils, the Publisher will deposit the final version of the Manuscript with PubMed Central on behalf of the Authors with public release at PubMed Central 12 months after publication of the final version of the Manuscript in the IJPSN. The Author has full rights for depositing the accepted manuscripts in the PubMed as per the funding agreements.

Corresponding Author Name: ______________________________ Signature: _________________________ Date: __________ Co-Author Name: _______________________________________ Signature: _________________________ Date: __________ Co-Author Name: _______________________________________ Signature: _________________________ Date: __________ Co-Author Name: _______________________________________ Signature: _________________________ Date: __________ Co-Author Name: _______________________________________ Signature: _________________________ Date: __________ Co-Author Name: _______________________________________ Signature: _________________________ Date: __________ Co-Author Name: _______________________________________ Signature: _________________________ Date: __________ ____________________________________________________________________________________________________________
Correspondence: Send a scanned copy of the completed form to: journal@bspbooks.net and Cc to: reddysamba@gmail.com